ColuracetamFor research use only. Not for human consumption.

For In Vitro Research Use Only – Not for Human or Veterinary Application

Coluracetam (MKC-231)

Coluracetam pairs the racetam side chain, 2-oxopyrrolidin-1-yl-acetamide, with a fused tetrahydrofuro[2,3-b]quinoline ring. Mitsubishi Chemical's Yokohama Research Center made it in the early 1990s as MKC-231. It later appeared as BCI-540 in a BrainCells Inc. Phase 2 study (2008–2009).

N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide · C19H23N3O3 · 341.4 g/mol · CAS 135463-81-9 · PubChem CID 214346

A choline-uptake enhancer, not an AMPA modulator

The primary pharmacology describes it as an enhancer of high-affinity choline uptake (HACU), the rate-limiting step in making acetylcholine. Some reviews call it an "AMPAkine", but we found no primary AMPA-receptor data behind that label.

• It raised choline uptake in hippocampal synaptosomes from rats whose cholinergic neurons had been damaged with AF64A, but not in normal rats.
• It didn't inhibit acetylcholinesterase or bind muscarinic receptors in the assays reported.
• It raised the Vmax of choline uptake and the number of hemicholinium-3 binding sites, and showed affinity for cloned CHT1 transporters. The authors propose that it shifts more CHT1 to the synaptic membrane, though the binding site isn't established.
• In AF64A-lesioned rats, effects on uptake persisted after repeated dosing, at times when the compound was no longer detectable in brain.

Research base

About a dozen PubMed papers, mostly from the originator. They cover AF64A lesion models in rats and mice, a phencyclidine-exposure model, glutamate-toxicity protection in cultured cortical neurons, and recent stress-induced bowel-motility models in rats, where it was used as a CHT1 tool compound. No primate work.

The certificate

The certificate linked above is our own NuMega Resonance Labs qNMR report for lot PCS-COL-2726O, dated October 27, 2026, showing 96.8%. 50 capsules of 10 mg per bottle.

References

• Choline uptake in AF64A-lesioned rats: PMID 8740080
• CHT1 mode of action: PMID 18461273
• Acetylcholine synthesis and release: PMID 18446264
• Persistence after repeated dosing: PMID 18461272
• BrainCells Phase 2 registration: NCT00621270
• PubChem: CID 214346

Disclaimer
This compound has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. All use must follow institutional and regulatory guidelines.

Terms of Sale
By purchasing, the buyer affirms they are a qualified researcher or institution. All sales are final. The purchaser assumes full responsibility for handling, use, and regulatory compliance. Coluracetam reference material is supplied for qualified in vitro laboratory research only — not for human or veterinary consumption, administration, compounding, dispensing, diagnostic use, therapeutic use, or patient use.